Search

CIGB 2020 Vaccine

CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. … As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.

BacTRL-spike

As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids.

Potassium aspartate

Covax-19™

Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.

Gam-COVID-Vac

Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials. … The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac Lyo).

SARS-CoV-2 Sclamp

The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established … Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.

IMM-101

IMM-101 is a heat-inactivated immune-activating mycobacterial product. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

Coronavirus-Like Particle COVID-19 Vaccine

A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged … The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection.

RUTI® Vaccine

Much like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. … Sponsored by Fundació Institut Germans Trias i Pujol, the RUTI® Vaccine is being tested for prevention of COVID-19 infection in a controlled trial with 315 healthcare worker participants (NCT04453488).

Buthiazide